GlassScriptPhysician profile
Jennifer J Smith
NPI 1962707042
$2,899.37
in general payments reported to CMS, 2019-2025
31 companies · $456 in 2025
The $456 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $516 · 2022: $144 · 2023: $1,344 · 2024: $439 · 2025: $456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,812 · Travel and Lodging: $374 · Education: $54.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,811.64 |
| Travel and Lodging | $374.42 |
| Education | $54.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $840.53 | 2023 | Synchromedii |
| Biotronik Nro, INC. | $411.13 | 2023-2024 | Biotronik, Prospera |
| Abbvie INC. | $283.68 | 2021-2025 | |
| Vertos Medical, INC. | $108.68 | 2022-2024 | Mild Device Kit |
| Amarin Pharma, INC. | $108.26 | 2021 | |
| Astellas Pharma US INC | $107.13 | 2021 | |
| Dexcom, INC. | $104.27 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $94.71 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $89.09 | 2021-2025 | Evenity, Prolia |
| Collegium Pharmaceutical, INC. | $85.92 | 2022-2024 | Xtampza, Belbuca |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $72.97 | 2024-2025 | Caplyta |
| Mylan Specialty L.P. | $57.07 | 2021 | |
| Abbott Laboratories | $52.31 | 2024-2025 | Aveir |
| Novartis Pharmaceuticals Corporation | $39.73 | 2021 | |
| Forte Bio-Pharma LLC | $39.44 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $36.49 | 2023-2024 | Nucala |
| Novo Nordisk INC | $34.90 | 2023-2024 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $32.03 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $31.00 | 2021 | |
| Boston Scientific Corporation | $30.55 | 2025 | Wavewriter Alpha Prime 16 |
| Nalu Medical, INC. | $29.47 | 2023 | Nalu Neurostimulation System |
| Almatica Pharma LLC | $29.47 | 2024-2025 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $28.02 | 2025 | Rexulti |
| Exact Sciences Corporation | $24.98 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $23.16 | 2021 | |
| Tactile Systems Technology INC | $21.42 | 2025 | Nimbl, Flexitouch Plus |
| Sumitomo Pharma America, INC. | $20.12 | 2025 | Gemtesa |
| Seqirus USA INC | $19.24 | 2021 | |
| Neurocrine Biosciences, INC. | $17.16 | 2021 | |
| Grt US Holding, INC. | $14.91 | 2022 | |
| Cook Medical LLC | $11.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.